Hims & Hers launched affordable, personalized low T treatments to boost energy & sexual health. They offer enclomiphene now, and in 2026, will add FDA-approved oral KYZATREX through a partnership with Marius Pharmaceuticals, plus injectables. Patients start with at-home blood tests.
GoodRx partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499/month to self-paying patients, expanding access for those without adequate insurance. This makes them available at over 70,000 U.S. pharmacies. Hims & Hers down.
Hims & Hers' Q2 profit surged to $42.5M, fueled by 31% subscriber growth (2.4M total). Revenue of $544.8M missed estimates, impacted by wholesale weakness, causing shares to fall. Full-year guidance maintained.
